This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Telik Announces Telintra® Clinical Publication At The 54th Annual Meeting Of The American Society Of Hematology

Stocks in this article: TELK

PALO ALTO, Calif., Dec. 12, 2012 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) announced today the publication of a clinical trial abstract in the proceedings of the 54 th Annual Meeting of the American Society of Hematology in Atlanta, Georgia.  The abstract, " Oral Ezatiostat HCl (Telintra), a Glutathione Analog Prodrug GSTP1-1 Inhibitor, for Treatment of Patients with Myeloid Growth Factor-Resistant Idiopathic Chronic Neutropenia (ICN)," by Roger M. Lyons, MD; Sharon T. Wilks, MD; and of David J. Friedman MD, PhD, of Cancer Care Centers of South Texas, US Oncology in San Antonio, Texas; and Shelby A. Young, RN, BSN, and Gail L. Brown, MD, of Telik, Inc., in Palo Alto, California, is available online at Blood (ASH Annual Meeting Abstracts) 2012 120: Abstract 4394.

This abstract reports the preliminary results of a clinical trial with ezatiostat to study the treatment of patients with idiopathic chronic neutropenia (ICN).  ICN is a rare group of blood disorders characterized by low circulating neutrophils, recurrent fevers, mucosal inflammation and serious systemic infections.  The risk and severity of these complications is related to abnormally low levels of white blood cells.  Most patients initially respond to treatment with granulocyte colony stimulating factors (G‑CSF); however, some patients fail to respond or become resistant to G‑CSF treatments.  Further, G‑CSF therapy is often associated with bone and muscle pain, low platelet counts and enlargement of the spleen.  Patients may need to be on G‑CSF for the rest of their lives, and these side effects can interfere with therapy.

Ezatiostat is an investigational agent in development for the treatment of ICN.  The compound is a glutathione S-transferase (GST) inhibitor that activates Jun kinase, which has been demonstrated to promote growth and maturation of hematopoietic progenitors.  Four patients with longstanding, severe ICN and inadequate absolute neutrophil count (ANC) response to G‑CSF were enrolled in this phase 2 trial.  These patients all had a history of frequent hospitalization for sepsis, prolonged courses of antibiotics and poor response to myeloid growth factors, including G‑CSF.  The patients were treated with orally administered ezatiostat.

Ezatiostat treatment of these ICN patients with grade 4 neutropenia who were not responsive to G‑CSF resulted in a durable increase in their white-blood-cell levels, leading to clinically significant reductions in serious infections.  Extended oral treatment with ezatiostat has been well tolerated in these patients and may be appropriate for longer-term therapy.  Ezatiostat is the first targeted GSTP1-1 inhibitor that has been shown to have a positive effect on white blood cell levels in ICN and may provide molecular insight into the pathophysiology of ICN.  These results suggest that further study is warranted of ezatiostat's potential role as an oral therapy alternative or adjunct to G‑CSF in the treatment of ICN in patients who are not responsive to G‑CSF.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,804.80 +26.65 0.15%
S&P 500 2,070.65 +9.42 0.46%
NASDAQ 4,765.38 +16.9840 0.36%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs